Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC Plan B in Canada?

This article was originally published in The Tan Sheet

Executive Summary

Canada's National Drug Scheduling Advisory Committee recommends Paladin Labs' application to move emergency contraceptive Plan B from behind-the-counter to full over-the-counter status, Paladin announces April 14. A 30-day comment period will follow NDSAC's recommendation to the National Association of Pharmacy Regulatory Authorities, an independent body that works with Health Canada, Paladin explains. NAPRA will decide whether to endorse the NDSAC recommendation after the comment period closes. "While there is no guarantee of NAPRA's decision, it usually follows NDSAC's recommendations," Paladin states. If NAPRA endorses the recommendation, pharmacies could sell Plan B OTC beginning "around mid-May," the firm says. Unlike the U.S., Canada does not have an 18-and-older requirement for behind-the-counter Plan B and would allow open access to the emergency contraceptive if the product goes OTC, the Montreal-based specialty pharmaceuticals firm explains. The firm acquired the exclusive Canadian distribution rights to Duramed's Plan B in December 1999...

You may also be interested in...



Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101576

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel